Target market Late-stage immunotherapy for critically ill patients with severe infections such as necrotizing soft tissue infections and sepsis-associated AKI. Potential high-value partnerships with large hospitals and critical care centers treating life-threatening infections.

Orphan and Fast Track Reltecimod has FDA/EMA Orphan Drug designation and FDA Fast Track, signaling regulatory familiarity and expedited pathways. Opportunities to collaborate with premium academic centers and selective payer strategies to leverage designation benefits.

Clinical milestones Phase 3 pivotal data in NSTI and registrational study in SA-AKI create near-term proof points. Sales approach can align with evidence generation needs, pursuing KOL endorsements and hospital formulary discussions around critical care immunomodulation.

Strategic partnerships Existing investor network and leadership appointments indicate readiness for co-development, manufacturing partnerships, and international expansion. Target biopharma collaborations for commercialization and global access in critical care settings.

Market potential Significant unmet need in severe infections with high mortality and no current therapy. Opportunity to position Reltecimod as a first-in-class immunomodulator in ICUs, with potential payor interest driven by improved organ failure resolution and reduced ICU stays.